India, Dec. 15 -- image credit- freepik

Akums Drugs & Pharmaceuticals, a Delhi-based Contract Development and Manufacturing Organization (CDMO), has announced the rollout of its enhanced Gabapentin Extended-Release (ER) formulation for the management of Postherpetic Neuralgia (PHN).

PHN, a chronic neuropathic pain condition that can persist for months after a shingles outbreak, affects nearly 10-20% of patients and becomes increasingly debilitating with age.Gabapentin remains a well-established therapy for neuropathic pain, but conventional formulations often require multiple daily doses and may be associated with variable absorption. Akums' new ER variant incorporates the company's proprietary RetenEx Technology, engineered to provide ...